Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 14/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 13/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.33 |
| ▸ | ITGAV | P06756 | 5/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016405 | 0.91 | ITGA4 (0.39) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22016403 | 0.91 | ITGB1 (0.44) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22017226 | 0.91 | ITGB1 (0.44) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22016336 | 0.90 | ITGB1 (0.43) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21957315 | 0.90 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22016617 | 0.90 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL21957313 | 0.90 | ITGB1 (0.49) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22016607 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL22016291 | 0.89 | ITGB1 (0.39) | ITGB1ITGA4ITGB7ITGB3ITGAV | |
| SCHEMBL22016652 | 0.89 | ITGB1 (0.41) | ITGB1ITGA4ITGB7ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ITGB1 3359/4885ITGA4 3235/4885ITGB7 2700/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 4/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.